open access
Angiotensin converting enzyme inhibitors versus angiotensin II type 1 receptor blockers in patients with acute myocardial infarction and prediabetes after successful implantation of newer-generation drug-eluting stents
, 1, 2, 3, 3, 4, 5, 3, 3, 3, 3, 3, 3
Affiliations- Division of Cardiology, Department of Inter nal Medicine, Kangwon National University School of Medicine, Chuncheon, Republic of Korea
- Department of Cardiology, Cardiovascular Center, Chonnam National Univer sity Hospital, Gwangju, Republic of Korea
- Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
- Cardiology Department, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea
- Division of Cardiology, Inje University College of Medicine, Haeundae Paik Hospital, Busan, Republic of Korea
open access
Abstract
Background: Because limited data are available, the present study investigated 2-year major clinical
outcomes after angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor
blockers (ARBs) therapy in patients with acute myocardial infarction (AMI) and prediabetes after successful
implantation of newer-generation drug-eluting stents (DESs).
Methods: Overall, 2932 patients with AMI and prediabetes were classified into two groups — the ACEIs
group (n = 2059) and the ARBs group (n = 873). The primary endpoint was the occurrence of patient-
-oriented composite outcome (POCO), defined as all-cause death, recurrent myocardial infarction (Re-MI),
or any repeat revascularization. The secondary endpoint was definite or probable stent thrombosis (ST).
Results: The cumulative incidences of POCO (adjusted hazard ratio [aHR]: 1.020; 95% confidence
interval [CI]: 0.740–1.404; p = 0.906), all-cause death (aHR: 1.394; 95% CI: 0.803–2.419; p = 0.238),
Re-MI (aHR: 1.210; 95% CI: 0.626–2.340; p = 0.570), any repeat revascularization (aHR: 1.150; 95%
CI: 0.713–1.855; p = 0.568), and ST (aHR: 1.736; 95% CI: 0.445–6.766; p = 0.427) were similar
between the groups. These results were confirmed after propensity score-adjusted analysis.
Conclusions: In this study, patients with AMI and prediabetes who received ACEIs or ARBs showed
comparable clinical outcomes during the 2-year follow-up period.
Abstract
Background: Because limited data are available, the present study investigated 2-year major clinical
outcomes after angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor
blockers (ARBs) therapy in patients with acute myocardial infarction (AMI) and prediabetes after successful
implantation of newer-generation drug-eluting stents (DESs).
Methods: Overall, 2932 patients with AMI and prediabetes were classified into two groups — the ACEIs
group (n = 2059) and the ARBs group (n = 873). The primary endpoint was the occurrence of patient-
-oriented composite outcome (POCO), defined as all-cause death, recurrent myocardial infarction (Re-MI),
or any repeat revascularization. The secondary endpoint was definite or probable stent thrombosis (ST).
Results: The cumulative incidences of POCO (adjusted hazard ratio [aHR]: 1.020; 95% confidence
interval [CI]: 0.740–1.404; p = 0.906), all-cause death (aHR: 1.394; 95% CI: 0.803–2.419; p = 0.238),
Re-MI (aHR: 1.210; 95% CI: 0.626–2.340; p = 0.570), any repeat revascularization (aHR: 1.150; 95%
CI: 0.713–1.855; p = 0.568), and ST (aHR: 1.736; 95% CI: 0.445–6.766; p = 0.427) were similar
between the groups. These results were confirmed after propensity score-adjusted analysis.
Conclusions: In this study, patients with AMI and prediabetes who received ACEIs or ARBs showed
comparable clinical outcomes during the 2-year follow-up period.
Keywords
angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, myocardial infarction, prediabetes, outcomes
Supp./Additional Files (1)
About this articleTitle
Angiotensin converting enzyme inhibitors versus angiotensin II type 1 receptor blockers in patients with acute myocardial infarction and prediabetes after successful implantation of newer-generation drug-eluting stents
Journal
Issue
Article type
Original Article
Pages
614-626
Published online
2021-09-30
Page views
2135
Article views/downloads
385
DOI
Pubmed
Bibliographic record
Cardiol J 2023;30(4):614-626.
Keywords
angiotensin-converting enzyme inhibitor
angiotensin receptor blocker
myocardial infarction
prediabetes
outcomes
Authors
Yong Hoon Kim
Ae-Young Her
Myung Ho Jeong
Byeong-Keuk Kim
Sung-Jin Hong
Sang-Ho Park
Seunghwan Kim
Chul-Min Ahn
Jung-Sun Kim
Young-Guk Ko
Donghoon Choi
Myeong-Ki Hong
Yangsoo Jang
References (39)- Sinnaeve PR, Steg PG, Fox KAA, et al. Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Arch Intern Med. 2009; 169(4): 402–409.
- Kolman L, Hu YC, Montgomery DG, et al. Prognostic value of admission fasting glucose levels in patients with acute coronary syndrome. Am J Cardiol. 2009; 104(4): 470–474.
- Huang Y, Cai X, Mai W, et al. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016; 355: i5953.
- Eleftheriadou A, Williams S, Nevitt S, et al. The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review. Diabetologia. 2021; 64(2): 288–303.
- Giraldez RR, Clare RM, Lopes RD, et al. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J. 2013; 165(6): 918–925.e2.
- Lim HS, MacFadyen RJ, Lip GYH. Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. Arch Intern Med. 2004; 164(16): 1737–1748.
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355(9200): 253–259.
- Verdecchia P, Sleight P, Mancia G, et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation. 2009; 120(14): 1380–1389.
- Braga MFB, Leiter LA. Role of renin-angiotensin system blockade in patients with diabetes mellitus. Am J Cardiol. 2009; 104(6): 835–839.
- Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177.
- O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61(4): e78–e7e140.
- Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(3): 267–315.
- Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 64(24): e139–e228.
- McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol. 2006; 47(4): 726–733.
- Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002; 360(9335): 752–760.
- Choi SY, Choi BG, Rha SW, et al. Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers in acute ST-segment elevation myocardial infarction patients with diabetes mellitus undergoing percutaneous coronary intervention. Int J Cardiol. 2017; 249: 48–54.
- Lv X, Zhang Y, Niu Y, et al. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2018; 97(15): e0256.
- Kim JuH, Chae SC, Oh DJ, et al. Multicenter Cohort Study of Acute Myocardial Infarction in Korea-Interim Analysis of the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry. Circ J. 2016; 80(6): 1427–1436.
- Grech ED. ABC of interventional cardiology: percutaneous coronary intervention. II: the procedure. BMJ. 2003; 326(7399): 1137–1140.
- American Diabetes Association. Standards of medical care in diabetes: 2010. Diabetes Care. 2010; 33 Suppl 1: S11–S61.
- Garcia-Garcia HM, McFadden EP, Farb A, et al. Academic Research Consortium. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018; 137(24): 2635–2650.
- Kim YH, Her AY, Jeong MHo, et al. Impact of stent generation on 2-year clinical outcomes in ST-segment elevation myocardial infarction patients with multivessel disease who underwent culprit-only or multivessel percutaneous coronary intervention. Catheter Cardiovasc Interv. 2020; 95(2): E40–E55.
- Bundhun PK, Wu ZiJ, Chen MH. Is there any significant difference in stent thrombosis between sirolimus and paclitaxel eluting stents?: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016; 95(5): e2651.
- Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diab Metab. 2004; 30(6): 498–505.
- Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014; 174(5): 773–785.
- Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011; 364(10): 907–917.
- Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ. 2004; 328(7438): 495.
- Wang K, Hu J, Luo T, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Kidney Blood Press Res. 2018; 43(3): 768–779.
- Zidek W, Schrader J, Lüders S, et al. Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study. Cardiovasc Diabetol. 2012; 11: 1.
- Min SeH, Kong SH, Lee JE, et al. Association of angiotensin-II levels with albuminuria in subjects with normal glucose metabolism, prediabetes, and type 2 diabetes mellitus. J Diabetes Complications. 2017; 31(10): 1499–1505.
- Zhang C, Knudson JD, Setty S, et al. Coronary arteriolar vasoconstriction to angiotensin II is augmented in prediabetic metabolic syndrome via activation of AT1 receptors. Am J Physiol Heart Circ Physiol. 2005; 288(5): H2154–H2162.
- Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006; 114(8): 838–854.
- Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ. 2004; 329(7477): 1248–1249.
- Kok MM, von Birgelen C, Sattar N, et al. Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population. EuroIntervention. 2018; 14(9): e1049–e1056.
- Yang JH, Hahn JY, Song YB, et al. Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study. BMJ. 2014; 349: g6650.
- International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32(7): 1327–1334.
- Iskandar S, Migahid A, Kamal D, et al. Glycated hemoglobin versus oral glucose tolerance test in the identification of subjects with prediabetes in Qatari population. BMC Endocr Disord. 2019; 19(1): 87.
- Silbernagel G, Grammer TB, Winkelmann BR, et al. Glycated hemoglobin predicts all-cause, cardiovascular, and cancer mortality in people without a history of diabetes undergoing coronary angiography. Diabetes Care. 2011; 34(6): 1355–1361.
- Kowalczyk J, Mazurek M, Zielinska T, et al. Prognostic significance of HbA1c in patients with AMI treated invasively and newly detected glucose abnormalities. Eur J Prev Cardiol. 2015; 22(6): 798–806.
